SCHEMBL6932438

SCHEMBL6932438

COc1nc2cc([N+](=O)[O-])c(OC)c([N+](=O)[O-])c2nc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TPMT P51580 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MCL1 Q07820 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 2/20 0.37
GALR2 O43603 1/20 0.37
LMNA P02545 1/20 0.37
GRM6 O15303 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
GRIA4 P48058 1/20 0.37
PKM P14618 1/20 0.35
HTT P42858 2/20 0.35
ERN1 O75460 1/20 0.34
TYMS P04818 1/20 0.34
TXNRD1 Q16881 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7960036 0.79 ALDH1A1 (0.40) ALDH1A1TSHRTDP1POLBGALR2
SCHEMBL7678635 0.77 GLP1R (0.50) TSHRMEN1KMT2A
SCHEMBL27395257 0.75 MAPT (0.38) ALDH1A1TSHRTDP1MEN1KMT2A
SCHEMBL6934708 0.75 MEN1 (0.59) ALDH1A1TDP1MEN1KMT2APOLB
SCHEMBL8146904 0.75 ALDH1A1 (0.54) ALDH1A1TPMTTSHRTDP1MCL1
SCHEMBL7961913 0.72 ALDH1A1 (0.35) ALDH1A1TSHRTDP1POLBGALR2
SCHEMBL7593494 0.72 TPMT (0.41) ALDH1A1TPMTTSHRTDP1MEN1
SCHEMBL5722679 0.72 POLB (0.45) ALDH1A1TDP1POLBGALR2LMNA
SCHEMBL30905617 0.72 GRIA1 (0.68) ALDH1A1TDP1MEN1KMT2APOLB
SCHEMBL7476184 0.71 GLP1R (0.44) ALDH1A1TSHRTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207886-A1 Preparation containing quinoxaline derivatives MERCK PATENT GMBH (DE) 2003-11-06 US claimed
EP-1267819-A2 PREPARATION CONTAINING QUINOXALINE DERIVATIVES MERCK PATENT GmbH (DE) 2003-01-02 EP claimed
WO-2001068047-A2 PREPARATION CONTAINING QUINOXALINE DERIVATIVES MERCK PATENT GMBH (DE) 2001-09-20 WO claimed
US-20030207886-A1 Preparation containing quinoxaline derivatives MERCK PATENT GMBH (DE) 2003-11-06 US disclosed
EP-1267819-A2 PREPARATION CONTAINING QUINOXALINE DERIVATIVES MERCK PATENT GmbH (DE) 2003-01-02 EP disclosed
WO-2001068047-A2 PREPARATION CONTAINING QUINOXALINE DERIVATIVES MERCK PATENT GMBH (DE) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207886-A1 Preparation containing quinoxaline derivatives CUTA, XPA, NQO2 ALDH1A1 1898/4885TPMT 1533/4885TSHR 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.